Annette Moore, MD
Hematology & Oncology · Kokomo, INNPI 1609818467
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 8.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,703 and has fallen 94.5% since, to $94 in 2025. That places this record below the midpoint for hematology & oncology clinicians in IN, where the typical reported total is $3,829.
Across 162 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$232
- Genentech USA, Inc.$214
- Pfizer$202
- Johnson & Johnson$154
- Tempus AI, Inc$146
- Hologic Sales And Service, LLC$145
- plus $2K from 31 others
Across 2 payments — averaging $640.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1K
What the payments were for
- Food & beverage$2,51396%
- Education$1134%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 15 | $232 |
| Genentech USA, Inc. | 14 | $214 |
| Pfizer | 15 | $202 |
| Johnson & Johnson(2 entities) | 12 | $154 |
| Tempus AI, Inc | 3 | $146 |
| Hologic Sales And Service, LLC | 7 | $145 |
| AstraZeneca(2 entities) | 9 | $140 |
| Eisai Inc. | 7 | $127 |
| Novartis | 6 | $115 |
| Bristol Myers Squibb | 7 | $97 |
| E.r. Squibb & Sons, L.L.C. | 5 | $76 |
| Sanofi | 4 | $76 |
| Incyte Corporation | 4 | $64 |
| Lilly USA, LLC | 4 | $62 |
| Exeltis, USA Inc. | 4 | $60 |
| Clovis Oncology, Inc. | 3 | $58 |
| Millicent US Inc | 3 | $56 |
| Gilead(2 entities) | 3 | $54 |
| Amgen | 4 | $54 |
| Bayer | 3 | $51 |
| Daiichi Sankyo Inc. | 3 | $48 |
| Exelixis Inc. | 3 | $47 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $44 |
| Boehringer Ingelheim | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $39 |
| Tersera Therapeutics LLC | 2 | $33 |
| AbbVie | 2 | $32 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $25 |
| Seagen Inc. | 2 | $24 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Aurobindo Pharma USA, Inc. | 1 | $15 |
| Verastem, Inc. | 1 | $15 |
| Dova Pharmaceuticals | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| GSK | 1 | $13 |
| Tesaro, Inc. | 1 | $13 |
| Rigel Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,626 in reported general payments places this provider in the 40th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 38 | $630,680 |
| OrserduElacestrant Hcl | 14 | $327,881 |
| PomalystPomalidomide | 14 | $298,338 |
| KisqaliRibociclib Succinate | 13 | $176,674 |
| VenclextaVenetoclax | 11 | $122,599 |
| EliquisApixaban | 37 | $43,319 |
| XareltoRivaroxaban | 12 | $17,213 |
| Exemestane | 22 | $10,707 |
| CreonLipase/Protease/Amylase | 12 | $8,517 |
| Anastrozole | 158 | $6,043 |
| Ondansetron Hcl | 77 | $2,662 |
| Letrozole | 25 | $1,448 |
| Tamoxifen Citrate | 36 | $1,368 |
| Acyclovir | 54 | $1,279 |
| Ibandronate Sodium | 33 | $1,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $97 | $630,68038 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $76 | $298,33814 claims |
| NovartisKisqali | $115 | $176,67413 claims |
| AbbVieVenclexta, Creon | $32 | $131,11623 claims |
| PfizerEliquis | $202 | $43,31937 claims |
| Johnson & JohnsonXarelto | $154 | $17,21312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Kokomo
- John SalterKokomo$19K
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Chandler ParkCorydon$661K
- Neel ShahDyer$464K
- Ahad SadiqFort Wayne$430K
- Ajay KandraMadison$408K
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.